IL298401A - Materials and methods for inhibiting viral infection, including coronavirus infection - Google Patents

Materials and methods for inhibiting viral infection, including coronavirus infection

Info

Publication number
IL298401A
IL298401A IL298401A IL29840122A IL298401A IL 298401 A IL298401 A IL 298401A IL 298401 A IL298401 A IL 298401A IL 29840122 A IL29840122 A IL 29840122A IL 298401 A IL298401 A IL 298401A
Authority
IL
Israel
Prior art keywords
biofilm
virus
seq
protein
composition
Prior art date
Application number
IL298401A
Other languages
English (en)
Hebrew (he)
Original Assignee
Quorum Innovations Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quorum Innovations Llc filed Critical Quorum Innovations Llc
Publication of IL298401A publication Critical patent/IL298401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL298401A 2020-06-06 2021-06-07 Materials and methods for inhibiting viral infection, including coronavirus infection IL298401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (1)

Publication Number Publication Date
IL298401A true IL298401A (en) 2023-01-01

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298401A IL298401A (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting viral infection, including coronavirus infection

Country Status (11)

Country Link
US (2) US11826390B2 (https=)
EP (1) EP4161558A4 (https=)
JP (1) JP2023529152A (https=)
KR (1) KR20230025853A (https=)
CN (1) CN116133669A (https=)
AU (1) AU2021286002A1 (https=)
BR (1) BR112022024911A2 (https=)
CA (1) CA3180737A1 (https=)
IL (1) IL298401A (https=)
MX (1) MX2022015439A (https=)
WO (1) WO2021248111A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006163A (es) * 2019-11-26 2022-06-17 Quorum Innovations Llc Nuevas composiciones de barrera protectora y usos de las mismas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
BRPI0822997A2 (pt) * 2008-09-04 2015-06-23 Om Pharma Extratos imunomoduladores de bactérias lactobacillus e métodos para fabricação e uso dos mesmos
KR101378608B1 (ko) * 2011-04-13 2014-03-27 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
DK3324986T3 (da) * 2015-07-20 2022-01-31 Quorum Innovations Llc Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion
CA3176797A1 (en) * 2020-05-06 2021-11-11 Nicholas T. Monsul Novel protein, and therapeutic and cosmetic uses thereof

Also Published As

Publication number Publication date
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
JP2023529152A (ja) 2023-07-07
EP4161558A1 (en) 2023-04-12
BR112022024911A2 (pt) 2022-12-27
US20240075083A1 (en) 2024-03-07
KR20230025853A (ko) 2023-02-23
WO2021248111A1 (en) 2021-12-09
EP4161558A4 (en) 2024-06-19
CN116133669A (zh) 2023-05-16
MX2022015439A (es) 2023-03-22
CA3180737A1 (en) 2021-12-09
WO2021248111A9 (en) 2022-12-22
US11826390B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
KR20130043625A (ko) 화합물들 및 그 용도
US12495800B2 (en) Protective barrier compositions, and uses thereof
US11649267B2 (en) Mitrecin A polypeptide with antimicrobial activity
US20240075083A1 (en) Materials and methods for inhibiting a viral infection, including a coronavirus infection
KR20180037185A (ko) 광범위의 항감염성 펩티드
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
CN107794232B (zh) 拮抗痤疮丙酸杆菌和革兰氏阳性菌生长的链球菌及其代谢产物
CN107794247A (zh) 一株痤疮丙酸杆菌噬菌体及其应用
US20250025528A1 (en) Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials
KR102586836B1 (ko) 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
Zhang et al. SmLMWPTP, a teleost low molecular weight protein tyrosine phosphatase, inhibits the immune response of peripheral blood leukocytes in a manner that depends on the conserved P-loop
Pandey et al. Novel Therapeutics: A Nemesis for Biofilm-forming Mycobacterium spp.
KR20170052946A (ko) 탄저균 특이 용균 단백질 ap50-31의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법
CN109535238B (zh) 一种经结构改造的抗菌肽Cec4或其盐及应用
KR102492395B1 (ko) 호랑나비 유충으로부터 유래된 펩타이드인 파필리오신-3 및 이의 용도
KR102430003B1 (ko) 아메리카왕거저리 유충으로부터 유래된 펩타이드인 조포바신-1 및 이의 용도
JP2009533478A (ja) 黄色ブドウ球菌感染症の治療用薬剤の製造のための活性成分としてｔｒａｐタンパク質自体の使用
Shesha Characterizing the Cytotoxicity of Pseudomonas aeruginosa PAO1 on Triple Negative Breast Cancer Cells